Chinese biotech company Asieris Pharmaceuticals has completed enrolment for its Phase Ib trial in the US to evaluate the safety, tolerability, and PK characteristics of APL-1202.

APL-1202 is the first oral and reversible methionine aminopeptidase II type (MetAP2) inhibitor and is currently being developed to treat non-muscle invasive bladder cancer (NMIBC), one of the most common malignant tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug has novel mechanisms of action of inhibiting tumour cell growth as well as angiogenesis.

The Phase Ib clinical trial will evaluate APL-1202 in combination with intravesical BCG in NMIBC patients who have received at least one induction course of intravesical BCG.

Patient follow-up is expected to be completed in September this year.

Asieris plans to launch a Phase II global clinical trial to evaluate the efficacy and safety of a combination of the drug with BCG in patients with NMIBC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Asieris co-founder, chairman and CEO Kevin Pan said: “The completion of enrolment for our APL-1202 Phase Ib clinical trial in the US represents a remarkable milestone for APL-1202’s global clinical development.

“Intravesical BCG is the first-line therapy for NMIBC globally, and through the clinical trials of APL-1202 in combination with intravesical BCG, we hope to provide a better treatment for NMIBC patients in the world.”

The common treatment of NMIBC at present is Trans-Urethral Resection of Bladder Tumour (TURBT).

Asieris develops and commercialises new drugs for the treatment of genitourinary tumours and related diseases.